MedTrace Logo

Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women

NCT00375297 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2006-09-12

No results posted yet for this study

Summary

This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD.

Conditions

Interventions

DRUG

sildenafil

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of New Mexico

    lead OTHER

Principal Investigators

  • George Nurnberg, MD · University of New Mexico School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375297 on ClinicalTrials.gov